Voyxact (Sibeprenlimab)

Sibeprenlimab is a medicine for IgA nephropathy, a kidney disease where an immune protein builds up and damages the kidneys. It is given as a shot under the skin. It blocks a signal that tells the immune system to make the harmful protein, which helps lower protein leaking into the urine.

Brand names:Voyxact
Medication

What people taking Voyxact (Sibeprenlimab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Voyxact (Sibeprenlimab) for IgA Nephropathy?

NameHow it went

About Voyxact (Sibeprenlimab)

What It's For

Sibeprenlimab, sold as Voyxact, is a prescription injection for adults with IgA nephropathy, a kidney disease in which clumps of an antibody called immunoglobulin A (IgA) lodge in the kidney's tiny filters. The resulting inflammation lets protein and blood leak into the urine and can slowly scar the kidneys, and some people eventually develop kidney failure. Voyxact is approved to lower the amount of protein in the urine in adults with primary IgA nephropathy (the form not caused by another disease) who are at risk of their kidney disease getting worse. The FDA granted this as an accelerated approval, meaning it was based on the drop in urine protein, which tends to predict better kidney outcomes, rather than on proof that kidney function lasts longer. When it was approved, it had not been established whether the drug slows kidney function decline over the long term. Final two-year results from the main trial, published in October 2026, found kidney function stayed roughly steady on sibeprenlimab while it declined on placebo, though the official approval still rests on the protein result. In that trial, sibeprenlimab was added to the highest tolerated dose of an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), blood pressure medicines that also protect the kidneys and are a standard foundation of IgA nephropathy care. It is not a replacement for those medicines, and it is not approved for children.

How It Works

IgA nephropathy begins with the immune system making an abnormal form of IgA (galactose-deficient IgA1). The body forms antibodies against it, and the resulting clumps settle in the kidney filters and trigger damage. A signaling protein called APRIL (a proliferation-inducing ligand) helps the immune cells that produce IgA survive and keep making it. Sibeprenlimab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds APRIL and blocks its signal, so the immune system makes less of the abnormal IgA. With fewer clumps reaching the kidneys, inflammation eases and less protein leaks into the urine. Because the drug works upstream on antibody production, it also lowers other antibody levels in the blood, which is why infection risk and vaccine timing matter.

Dosage & Administration

Voyxact comes as a single-dose prefilled syringe and is injected under the skin of the front of the thigh or the abdomen once every four weeks. A caregiver can also use the back of the upper arm. Most people give the injection themselves at home or have a caregiver do it, after a healthcare professional has shown them how. The syringes are kept in the refrigerator and need 15 to 30 minutes to reach room temperature before injecting. Once warmed, a syringe should not go back in the refrigerator, and it should not be used after seven days at room temperature. If a dose is missed, give it as soon as possible, then continue every four weeks from that new date. Rotate injection sites and avoid skin that is bruised, scarred, tender or red.

Side Effects

In the main trial, side effects were mostly mild or moderate and rarely led people to stop treatment. The most common were colds and other upper respiratory infections, and redness or irritation where the injection was given. Both happened only slightly more often than with placebo injections. A serious allergic reaction is possible. Stop using the medicine and get emergency medical care for trouble breathing, swelling of the face, lips or throat, or widespread hives after an injection. People who have had a serious allergic reaction to sibeprenlimab or its ingredients should not use it.

Interactions & Warnings

Because sibeprenlimab lowers antibody production, it may make infections more likely, and people who already have chronic or repeated infections may be at higher risk of a serious one. Before starting, the care team checks for any active infection. Tell them about fever, chills, a persistent cough, painful urination or other signs of infection during treatment; they may pause the drug until a serious infection is under control. Live vaccines, which contain a weakened form of a virus or bacterium, are not recommended within 30 days before starting or at any point during treatment. Sibeprenlimab may also make other vaccines work less well, so it helps to review vaccinations before the first dose. There is little information on combining it with other immune-suppressing medicines, such as steroids taken by mouth, so the prescriber should know about any you take now or have taken recently. There are no data on its use in human pregnancy. Antibody medicines like this one cross the placenta, especially in the second and third trimesters, so anyone pregnant or planning pregnancy should discuss it with the kidney specialist. It is also unknown whether it passes into breast milk.

What to Expect

Sibeprenlimab works gradually. In the main trial, urine protein had fallen by about half on average after nine months, while it rose slightly with placebo. Responses vary, and progress is tracked with urine tests that measure protein (often a urine protein-to-creatinine ratio) and blood tests of kidney function, usually reported as eGFR, the estimated glomerular filtration rate. A higher eGFR means the kidneys are filtering better, and a steady eGFR over time is the goal. Treatment is ongoing rather than a short course, and blood pressure control and the kidney-protecting medicines usually continue alongside it. Some people develop antibodies against the drug itself, which in the trial was linked to a somewhat smaller drop in urine protein, though what that means for any one person is unclear. Because the long-term evidence is still being reviewed by regulators, regular check-ins with the kidney team help decide whether it is working well enough to continue.

Questions to Ask Your Doctor

  1. 1.How high is my risk of my kidney disease progressing, and why is sibeprenlimab a good fit compared with other IgA nephropathy treatments?
  2. 2.What drop in urine protein or change in eGFR would tell us it is working, and when will we check?
  3. 3.Which vaccines should I get before starting, and are any of my current medicines a concern?
  4. 4.What signs of infection should prompt a call, and would we pause treatment if I get sick?
  5. 5.How long would I stay on it, and what would happen to my kidneys if I stopped?

Last reviewed • Oct 2026

Educational content, not medical advice.